LFVN vs. CMRX, LPTX, QTTB, AFMD, ALRN, ETON, IFRX, ONCY, RVPH, and MRNS
Should you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Chimerix (CMRX), Leap Therapeutics (LPTX), Q32 Bio (QTTB), Affimed (AFMD), Aileron Therapeutics (ALRN), Eton Pharmaceuticals (ETON), InflaRx (IFRX), Oncolytics Biotech (ONCY), Reviva Pharmaceuticals (RVPH), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical preparations" industry.
Chimerix (NASDAQ:CMRX) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.
Chimerix currently has a consensus target price of $8.00, suggesting a potential upside of 797.87%. Given LifeVantage's higher probable upside, equities analysts plainly believe Chimerix is more favorable than LifeVantage.
Chimerix received 165 more outperform votes than LifeVantage when rated by MarketBeat users. However, 77.82% of users gave LifeVantage an outperform vote while only 64.12% of users gave Chimerix an outperform vote.
Chimerix has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
LifeVantage has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
45.4% of Chimerix shares are owned by institutional investors. Comparatively, 35.3% of LifeVantage shares are owned by institutional investors. 10.0% of Chimerix shares are owned by insiders. Comparatively, 6.8% of LifeVantage shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Chimerix had 1 more articles in the media than LifeVantage. MarketBeat recorded 4 mentions for Chimerix and 3 mentions for LifeVantage. Chimerix's average media sentiment score of 0.43 beat LifeVantage's score of 0.30 indicating that LifeVantage is being referred to more favorably in the news media.
LifeVantage has a net margin of 1.40% compared to LifeVantage's net margin of -25,337.96%. Chimerix's return on equity of 19.96% beat LifeVantage's return on equity.
Summary
LifeVantage beats Chimerix on 9 of the 17 factors compared between the two stocks.
Get LifeVantage News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LifeVantage Competitors List
Related Companies and Tools
